Effectiveness and safety of opicapone in Parkinson’s disease patients with motor fluctuations: the OPTIPARK open-label study  

作　　者：Heinz Reichmann Andrew Lees José-Francisco Rocha Diogo Magalhaes Patrício Soares-da-Silva the OPTIPARK investigators 

机构地区：[1]Department of Neurology,University of Dresden,Dresden,Germany [2]University College London,Reta Lila Weston Institute,London,UK [3]Global Parkinson’s Disease Department,BIAL–Portela&CA S.A,Coronado,Portugal [4]Research and Development Department,BIAL–Portela&CA S.A,da Siderurgia Nacional,4745-457 S Mamede do Coronado,Portugal [5]Department of Pharmacology and Therapeutics,Faculty of Medicine,University Porto,Porto,Portugal [6]MedInUP,Center for Drug Discovery and Innovative Medicines,University Porto,Porto,Portugal [7]不详

出　　处：《Translational Neurodegeneration》2020年第1期96-104,共9页转化神经变性病（英文）

基　　金：The study was funded by BIAL;Three authors(JFR,DM and PSS)were employed by the funder and participated in the study design,data collection,data management,and data analysis;The funder of the study had no other role in data interpretation or in the decision to submit the manuscript for publication;BIAL also supported reporting of study results by procuring medical writing support.

摘　　要：Background:The efficacy and safety of opicapone,a once-daily catechol-O-methyltransferase inhibitor,have been established in two large randomized,placebo-controlled,multinational pivotal trials.Still,clinical evidence from routine practice is needed to complement the data from the pivotal trials.Methods:OPTIPARK(NCT02847442)was a prospective,open-label,single-arm trial conducted in Germany and the UK under clinical practice conditions.Patients with Parkinson’s disease and motor fluctuations were treated with opicapone 50 mg for 3(Germany)or 6(UK)months in addition to their current levodopa and other antiparkinsonian treatments.The primary endpoint was the Clinician’s Global Impression of Change(CGI-C)after 3 months.Secondary assessments included Patient Global Impressions of Change(PGI-C),the Unified Parkinson’s Disease Rating Scale(UPDRS),Parkinson’s Disease Questionnaire(PDQ-8),and the Non-Motor Symptoms Scale(NMSS).Safety assessments included evaluation of treatment-emergent adverse events(TEAEs)and serious adverse events(SAEs).Results:Of the 506 patients enrolled,495(97.8%)took at least one dose of opicapone.Of these,393(79.4%)patients completed 3 months of treatment.Overall,71.3 and 76.9%of patients experienced any improvement on CGI-C and PGI-C after 3 months,respectively(full analysis set).At 6 months,for UK subgroup only(n=95),85.3%of patients were judged by investigators as improved since commencing treatment.UPDRS scores at 3 months showed statistically significant improvements in activities of daily living during OFF(mean±SD change from baseline:?3.0±4.6,p<0.0001)and motor scores during ON(?4.6±8.1,p<0.0001).The mean±SD improvements of?3.4±12.8 points for PDQ-8 and-6.8±19.7 points for NMSS were statistically significant versus baseline(both p<0.0001).Most of TEAEs(94.8%of events)were of mild or moderate intensity.TEAEs considered to be at least possibly related to opicapone were reported for 45.1%of patients,with dyskinesia(11.5%)and dry mouth(6.5%)being the most frequently reported.Serio

关 键 词：LEVODOPA Motor FLUCTUATIONS OPEN-LABEL Opicapone Parkinson’s disease 

分 类 号：R742.5[医药卫生—神经病学与精神病学]